at Nasdaq.com (Dec 10, 2014)
Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an...
Insmed Incorporated (INSM +2%) gains after the FDA grants orphan drug designation to Arikace, an inhaler for treating infections caused by non-tuberculous mycobacteria. The company notes that there's currently no FDA-approved treatment for this particular NTM lung infection.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at CNBC.com (Jun 18, 2014)
at CNBC.com (Mar 26, 2014)
at CNBC.com (Oct 27, 2011)
at MarketWatch.com (Oct 10, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs